Navigation Links
An Aid to Tailoring Prostate Cancer Treatment
Date:5/16/2009

Study identifies factors to help decide how aggressive therapy should be

FRIDAY, May 15 (HealthDay News) -- Researchers claim to have found a way to better customize the treatment of prostate cancer.

Four risk factors that can help predict how long men could survive with metastatic prostate cancer have been identified by researchers from the Duke Comprehensive Cancer Center, who say such information would help doctors individualize treatments.

"There is a need for identification of accurate and simple-to-use prognostic factors for men with prostate cancer that has spread beyond the prostate," Andrew Armstrong, a medical oncologist at Duke and the lead investigator for the study, said in a university news release. "Our study was aimed at developing accurate predictors which may be used to assist in clinical decision making and also in planning clinical trials for men whose disease has stopped responding to hormone therapy."

By studying the records of more than 1,000 men who were taking part in a study of the chemotherapeutic drug docetaxel and its effect on metastatic prostate cancer, the researchers found four risk factors that predicted how well someone would respond to treatment:

  • The presence of cancer-related pain
  • Anemia
  • How extensively the cancer has spread to other organs
  • The progression of cancer in bone

"Using these predictors, we were able to assign patients to risk groups of good -- indicating an average survival of about two years; intermediate -- with survival of about 1.5 years; and poor -- with survival of less than a year," Armstrong said.

"By knowing a patient's prognosis and expected responses to chemotherapy, we are better able to discuss and determine whether a more- or less-aggressive treatment plan might be advisable," he said.

Another benefit is long-range knowledge, Armstrong said. Identifying men's prognoses and how they are expected to respond to treatment also would help determine whether a drug is ready for a phase 2 trial, which test a treatment that has been shown to help some people. It usually compares a newer treatment to the gold standard, or best-known treatment.

"We're eager to use this information to accurately estimate what to expect with current therapies," Armstrong said.

The findings are to be made available to those attending the American Society of Clinical Oncology's annual meeting in Orlando, Fla., in late May.

More information

The American Cancer Society has more about prostate cancer.



-- Dennis Thompson



SOURCE: Duke University, news release, May 14, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tailoring glioblastoma therapies: 1 size does not fit all
2. The Childrens Hospital of Philadelphia Receives Grant to Study Tailoring Pediatric Preventive Care to Individual Needs
3. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
4. First biomarker discovered that predicts prostate cancer outcome
5. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
6. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
7. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
8. Red wine compound shown to prevent prostate cancer
9. Barbershop Talks Cut Black Mens Prostate Cancer Risk
10. Generic prostate drug helps find high-risk cancers early
11. Finasteride unlikely to induce high grade prostate cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
An Aid to Tailoring Prostate Cancer Treatment
(Date:4/29/2016)... (PRWEB) , ... April 30, 2016 , ... ... engineer of patented products, announces the Pick Up Springboard, an automotive invention that ... Light Truck Manufacturing industry is worth $162 billion," says Scott Cooper, CEO and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Awakening , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress ... Onnit brain and mood optimization products to the store is just one more ...
(Date:4/29/2016)... VA (PRWEB) , ... April 29, 2016 , ... ... with student loans more flexibility in repaying their loans, more information about their ... a time when total outstanding student loan debt, including federal and private loans, ...
(Date:4/29/2016)... Philadelphia, PA (PRWEB) , ... April 29, 2016 ... ... Pennsylvania announced that student team BioCellection won the $30,000 Perlman Grand Prize of ... Impact Prize, the Gloeckner Undergraduate Award, the Michelson People‚Äôs Choice Award, and the ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Dr. Robert Mondavi, ... treatments to improve smiles. Cosmetic dentistry is a fast-growing field as more patients are ... allows patients to learn more about the options currently available to them and which ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company ... and vaccines for the treatment of cancer & metastatic disease, ... Growth Capital Expo to be held on May 3 ... in Las Vegas, Nevada.  The Company presentation will be ... by Dr. John N. Bonfiglio a TapImmune Board ...
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
(Date:4/27/2016)... April 27, 2016  Bayer Animal Health today ... from the University of Florida College of Veterinary ... Excellence in Communication Award (BECA). Brittany was selected ... awarded a total of $70,000 in scholarship funds ... years, Bayer has provided a total of $232,500 ...
Breaking Medicine Technology: